Abstract: There is provided a method of treating onychomycosis of the nail, comprising topical application of a pharmaceutical composition comprising an antifungal allylamine compound and a non-aqueous solvent system, which method comprises a loading phase, during which the pharmaceutical composition is administered at least three times a week, followed by a maintenance phase, during which the pharmaceutical composition is administered no more than two times per week. There are further provided pharmaceutical compositions suitable for topical application to the nail comprising an antifungal allylamine compound, an organic acid component and a diol component, as defined herein, and their use in methods of treating onychomycosis.

Abstract: The invention provides a method of treating chronic rhinosinusitis such as allergic fungal sinusitis comprising daily oral administration of a composition from more than 500 mg to about 800 mg, preferably about 625 mg or 725 mg terbinafine base equivalent as hydrochloride, or a molar equivalent in other acid addition salt or free base form, for a duration effective to reduce the symptoms of, or eliminate chronic rhinosinusitis; it further concerns the use of terbinafine in the manufacture of a corresponding medicament, and packs containing a plurality of corresponding compositions and medicaments.

Abstract: A topical composition suitable for application to skin comprising an amount of antioxidant action vitamin and vitamin precursor sufficient to bring about an effect selected from the group consisting of a level of vitamin on the skin significantly above the amount of vitamin on normal vitamin untreated skin for a period of treating four hours after application of the said vitamin containing composition, a reduction of lipid peroxide levels brought about by an insult to the skin wherein the skin is treated with the said vitamin containing composition prior to said insult, a level of skin vitamin which is significantly above the level of vitamin on the skin brought about by oral ingestion of the vitamin, or a combination of any of a, b, or c.

Abstract: A method for demonstrating the effectiveness of an antioxidant containing composition in neutralizing a free radical bearing entity which comprises:

Abstract: A topical composition suitable for application to skin comprising an amount of antioxidant action vitamin and vitamin precursor sufficient to bring about an effect selected from the group consisting of a level of vitamin on the skin significantly above the amount of vitamin on normal vitamin untreated skin for a period of treating four hours after application of the said vitamin containing composition, a reduction of lipid peroxide levels brought about by an insult to the skin wherein the skin is treated with the said vitamin containing composition prior to said insult, a level of skin vitamin which is significantly above the level of vitamin on the skin brought about by oral ingestion of the vitamin, or a combination of any of a, b, or c.

Abstract: The sequences encoding two isoforms of human cellular retinoid acid binding proteins, CRABP-I and CRABP-II, have been cloned and sequenced and are set forth with their corresponding amino acid sequences. The identification of human CRABP nucleic and amino acid sequences provides the basis for the construction of recombinant human CRABP vectors and expression constructs. Human CRABP can also be synthesized or produced ex vivo, e.g. in bacterial or other production systems. Ligand binding assays, including recombinant and chimeric receptor reporter assays, and direct and competition hybridization assays employing the human CRABP sequences herein described can be used to test drugs for retinoid induction and tissue specificity for pathologies in which retinoids are implicated. Immunoassays utilizing antibodies or binding fragments produced to human CRABP can also be used to test patient tissues for the presence and levels of CRABP for diagnosis and to monitor treatment.

Abstract: The sequences encoding two isoforms of human cellular retinoid acid binding proteins, CRABP-I and CRABP-II, have been cloned and sequenced and are set forth with their corresponding amino acid sequences. The identification of human CRABP nucleic and amino acid sequences provides the basis for the construction of recombinant human CRABP vectors and expression constructs. Human CRABP can also be synthesized or produced ex vivo, e.g. in bacterial or other production systems. Ligand binding assays, including recombinant and chimeric receptor reporter assays, and direct and competition hybridization assays employing the human CRABP sequences herein described can be used to test drugs for retinoid induction and tissue specificity for pathologies in which retinoids are implicated. Immunoassays utilizing antibodies or binding fragments produced to human CRABP can also be used to test patient tissues for the presence and levels of CRABP for diagnosis and to monitor treatment.